PUBLISHER: Roots Analysis | PRODUCT CODE: 1830063
PUBLISHER: Roots Analysis | PRODUCT CODE: 1830063
The vaccine development companies produced an estimated 7 billion doses of vaccines globally, in the year 2024 and are expected to produce around 8 billion doses in 2025.
Vaccine Developers Market: Growth and Trends
Vaccine is a specialized medical product formulated to activate the body's immune system, enabling it to recognize and protect against specific diseases over the long term. The development of vaccines typically involves using either weakened or inactivated forms of the disease-causing microorganism, or including crucial antigenic components from the pathogen, such as structural proteins and inactivated toxins. By introducing these components, vaccines assist the immune system in recognizing and combating the real pathogen if encountered in the future.
According to World Health Organization, vaccines are categorized into two types, namely preventive (prophylactic) vaccines, which are administered to protect individuals from contracting diseases, and therapeutic vaccines, which are utilized as treatment regimens to help the body fight existing illnesses. Currently, pharmaceutical companies offer numerous vaccines, and many are undergoing clinical trials or are in various stages of development, targeting a wide range of serious and debilitating conditions.
Recently, the Coalition for Epidemic Preparedness Innovations (CEPI) has made a significant new investment of USD 24 million in the Vaccine and Infectious Disease Organization (VIDO), aiming to bolster global preparedness for future infectious disease outbreaks as the world continues to combat the last pandemic.
Significantly, the development and approval of innovative vaccines, by vaccine development companies, such as mRNA, DNA, and recombinant vaccines, are significant trends influencing the competitive landscape of vaccines market.
Vaccine Developers Market: Key Insights
The report delves into the current state of the vaccine developers market and identifies potential growth opportunities within industry. Some key findings from the report include:
Vaccine Developers Market: Key Segments
Competitive Landscape of Vaccine Development Companies
The current market landscape takes into account more than 200 vaccine developers including very large, large, mid-sized and small companies. These vaccine developers have the required expertise to develop different types of vaccines, such as cancer vaccines, mRNA vaccines, RSV vaccines and DNA vaccine across different key geographical regions. Notably, most companies are based in North America, followed by Asia-Pacific; this is reflective of the high market potential in these regions. Notable examples of recently established vaccine developers (established post-2020, in alphabetical order) include AbVacc, Auro Vaccines, HilleVax, Innovac Therapeutics, Nuravax, Pyrojas and Vernagen.
Rising Partnerships and Collaborations Activity to Foster Progress and Innovation in Expanding their Capabilities
The vaccine development market has witnessed a decent partnership activity in the past few years. Notably, in the last five years, companies based in North America and Europe have inked majority of the partnerships to strengthen their development processes of vaccines. Most of the partnerships signed in this domain are manufacturing agreements, followed by product development agreements. This is indicative of the persistent efforts of vaccine developers to advance their research and development activities for the development of different types of vaccines.
Recent Facility Expansions to Improve Capacity
The vaccine development players have witnessed significant facility expansions to meet growing global demand and advance manufacturing capabilities. In March 2025, Merck opened a USD 1 billion state-of-the-art vaccine manufacturing plant in North Carolina, incorporating cutting-edge technologies, such as AI and 3D printing. Other key players, including Lonza and WuXi Biologics, have also expanded their new mRNA vaccines in development and viral vector vaccine capacities worldwide. These investments emphasize the sector's commitment to increasing production, boosting innovation, and reinforcing supply chains to fulfill future vaccine needs.
Example Players in the Vaccine Development Companies Landscape
Vaccine Development Companies Landscape: Research Coverage
Key Questions Answered in this Report
Reasons to Buy this Report
Additional Benefits